Onchocerciasis is a major blinding disease in parts of Africa, the Yemen, and Central and South America. The parasite, Onchocerca volvulus, is a filarial nematode which is transmitted by blackflies of the genus Simulium. It infects an estimated 18 million people worldwide of which about 350 000 are blind and a similar number are visually impaired. 1 Blinding lesions may affect the anterior and posterior segments and include sclerosing keratitis, iridocyclitis, optic atrophy, and chorioretinopathy.2 Posterior segment lesions, particularly chorioretinopathy, account for most visual loss in this disease .35 Amocarzine is an isothiocyanate derivative with both macrofilaricidal6 and microfilaricidal effects. 7 The clinical efficacy of this compound in onchocerciasis has been demonstrated in field trials in Ecuador8 and Guatemala. 9 There are no published reports of the long term effects of this promising macrofilaricide on posterior segment disease. This is of particular importance in the light of the well documented adverse effects of other filaricidal drugs on the posterior segment.'0 11 The natural history of onchocercal chorioretinopathy is poorly understood. Most epidemiological studies which have examined this process have linked its presence with skin and ocular microfilarial indices. [12] [13] [14] However, onchocercal chorioretinopathy is a chronic progressive inflammatory process3 that continues to progress despite the reduction of microfilarial levels by chemotherapy3 15 16 or vector control. '7 This latter observation has generated renewed interest into the pathogenesis of the lesion. [18] [19] [20] This study examined longitudinally the relation between the evolution of chorioretinopathy and detailed changes in microfilarial burdens in O volvulus infected subjects who had received the oral macrofilaricide amocarzine.
Materials and methods

STUDY POPUtATION
Patients were recruited from 33 villages in the hyperendemic area in the rain forest focus on onchocerciasis in the Santiago river basin of Esmeraldas Province in Ecuador. The communities living in this area included both indigenous Amerindian (Chachi tribe) and Ecuadorians of African descent (AfroEcuadorians). The ethnographic features of these communities have been described elsewhere.2l
Patients were selected in four separate cohorts starting in February 1988, March 1989, March 1990, and March 1991 and were followed up for 5, 4, 3, and 2 years respectively. All study participants were volunteers who were known to have palpable nodules and microfilariae in skin snips from a previous survey. The different cohorts received different regimens of oral amocarzine as part of a study to investigate the efficacy, tolerability, and pharmacokinetics of amocarzine and to optimise dosage regimens.8 Amocarzine was administered biannually as follows : 1988, 1990 , and 1992 in the 5 year cohort; 1989 and 1991 in the 4 year cohort; 1990 and 1992 in the 3 year cohort; and 1991 in the 2 year cohort. The total dose administered to each cohort is shown in Table 1 . Selection of the first cohort was restricted to males with moderate skin microfilarial (mf) counts (range 30-50 mf/mg), while microfilarial intensity did not Cooper, Proaio, Beltran, Anselmi, Guderian A total of 369 individuals were recruited into the four cohorts. Of these 294 (79-7%) were followed completely and are included in the analysis. The age distribution of the four cohorts is shown in Table 2 .
A total of 75 (20.3%) individuals of the 369 starting the study were lost to follow up. These individuals left the study because of emigration (62/75) from the study area or death (10/75).
Loss of data excluded the remaining three from the analysis. Loss to follow up affected 33*3% of the 5 year cohort, 15-7% of the 4 year cohort, 30-6% of the 3 year cohort, and 16-8% of those followed for 2 years. There Times of amocarzine administration are given in the text.
INCIDENCE OF CHORIORETINOPATHY
The incidence of RPE atrophy and chorioretinal scarring in the four cohorts is shown in Table 1 . The incidence of RPE atrophy remained remarkably constant in all four cohorts. However, the 4 year cohort had a much higher incidence of RPE atrophy than the other three cohorts. The incidence of chorioretinal scarring increased with greater period of follow up.
DEVELOPMENT OF NEW AND EXTENSION OF OLD CHORIORETINAL LESIONS
These were seen in 97 (330O%) individuals; new lesions (type 1) developed in 68 individuals and progression of existing disease (type 2) was seen in 29 individuals (16 developed symmetrical new lesions, six showed evidence of extension of an existing lesion, and seven showed a combination of these).
The incidence rates for both types of lesions are shown in Table 3 . The risk of developing new lesions (type 1) was greater with increasing length of follow up. The risk of progression of existing chorioretinal disease (type 2) also increased with length of follow up but was greater in the 4 year than the 5 year cohort. The risk of disease progression (type 2) was greater than that of developing a new lesion (type 1) in all cohorts.
Resolution of chorioretinal lesions was seen in one individual in the 2 year cohort (0O8%). This took the form of the disappearance of early temporal RPE atrophy. Cumulative intensities in the skin (p<005) and eye (p<005) correlated with the development of new chorioretinal lesions. The development of new lesions was strongly associated with both age (p<0001) and period of follow up (p<0-001). No association with race or sex was seen. After controlling for age and cohort, an association remained between cumulative skin infection intensity and the development of new chorioretinal lesions (p<001). Angiographic studies performed up to 1 year after administration of amocarzine remained normal,9 though early transient changes might have been missed. In this study, all study participants were re-examined 1 week after amocarzine administration at each treatment time and none of the lesions documented was first noted at this time point. The method by which disease was recorded was subject to error which was minimised by using two experienced ophthalmologists (RP and CB), each of whom examined the same patients over the study period. Only one individual was recorded as having an improvement in chorioretinal disease which suggests that the fundal findings were accurately and consistently reported. This and other studies3 12 have demonstrated that onchocercal chorioretinopathy is progressive and evidence of disease resolution is generally only seen in the transient post-treatment defects in the RPE described above.
The chorioretinal lesions seen in this onchocerciasis focus22 are identical to those described elsewhere as typical of onchocerciasis.3 30 The discrete pigmented atrophic scars of ocular toxoplasmosis were recorded in 11 (or 4%) of the study participants (data not shown) of which seven had evidence of concurrent onchocercal chorioretinopathy. The latter was characterised by diffuse, pigmented chorioretinal scars associated with RPE atrophy. Mottling of the RPE attributable to ocular toxoplasmosis is a rare findings.3' 32 No abnormalities of the retina attributable to other disease processes were recorded. High incidence rates of new chorioretinal lesions and extension of existing disease were seen in this study. Two other longitudinal studies have attempted to estimate the cumulative incidence for the development and deterioration of posterior segment lesions: Anderson and co-workers'3 followed up communities in Cameroon over 4 years and estimated the incidence of development/deterioration of chorioretinopathy to be 6-7% in the rain forest and 4-2% in the savanna. Between villages this risk varied from 0 to 23% in both regions.33 The second study followed 263 individuals (suramin or no treatment) for 14-15 years in the Nigerian savanna.12 From data available in this report, incidence risks for the development/deterioration of posterior segment lesions can be calculated; extension of existing lesions (type 2) was seen in 45.2% ofuntreated and 52-6% oftreated subjects and new lesions (type 1) in 24.8% of the untreated and 13 8% ofthose treated. These estimates are considerably less than the equivalent estimates obtained in this study (comparing the 4 year cohort with the first study and the 5 year cohort with the second study).
The high incidence of chorioretinal lesions seen in this study ( This was particularly important in this study because of the long term reduction in microfilarial burdens that followed amocarzine therapy.
Microfilarial counts in the skin seem to be more important than those in the anterior chamber.13 This may simply reflect the larger error involved in the assessment of anterior chamber microfilariae as the accuracy of assessment is strongly dependent on the cooperation of the patient both before and during examination (and the skill of the observer). A number of workers have demonstrated that the level of ocular parasitisation is strongly associated with the development of new chorioretinal lesions.12 13 The presence of head nodules is also a useful index of risk38 and following nodulectomy, only those with greater than 15 microfilariae at the outer canthus developed new chorioretinal lesions. 39 The presence of microfilariae in vitreous has also been associated with development of chorioretinopathy. 13 There can be little doubt, therefore, that ocular microfilariae are essential for the induction of chorioretinal lesions. Retinal damage would result from the inflammatory reactions that follow the death of intraretinal microfilariae. The finding of RPE disturbances in a classically onchocercal distribution (for example, the temporal edge of the macula) soon after administration of diethylcarbamazine11 strongly supports this hypothesis.
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